Unleashing the power of next generation cancer treatments

View Pipeline

Pipeline

AmMax has built a robust oncology pipeline by leveraging its translational expertise with its lead program, AMB-066, supported by compelling preclinical data and a well-established safety profile across 6 completed clinical trials.

AMB
066 VIEW AMB
104 VIEW

Dr. Van Morris, Principal Investigator, MD Anderson Cancer Center, discusses NCT06617858:

a Phase 2 proof of concept study to test AMB-066 for treating CRC MRD. This trial is currently recruiting.

Latest News

All News
Mar 11, 2025

AmMax Bio Announces Presentation at BIO-Europe Spring 2025

 Read More Jan 27, 2025

AmMax Bio Announces First Patient Dosed in Phase 2a Study Evaluating AMB-066 in Patients with Colorectal Cancer Minimal Residual Disease

 Read More Dec 10, 2024

AmMax Bio and MD Anderson Announce Agreements to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease

 Read More
All News